ReviewOncology (Williston Park, N.Y.)2014
Updates on the management of breast cancer brain metastases.
Review in Oncology (Williston Park, N.Y.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 47 citations in OpenAlex.
- Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial.The oncologist · 2021Trial
- ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.Future oncology (London, England) · 2019Trial
- ANG1005 for breast cancer brain metastases: correlation betweenBreast cancer research and treatment · 2016Trial
- Molecular landscape and emerging therapeutic strategies in breast cancer brain metastasis.Therapeutic advances in medical oncology · 2023Review
- Designing Patient-Driven, Tissue-Engineered Models of Primary and Metastatic Breast Cancer.Bioengineering (Basel, Switzerland) · 2022Article
- Molecular Mechanisms Associated with Brain Metastases in HER2-Positive and Triple Negative Breast Cancers.Cancers · 2021Review
- Drug resistance occurred in a newly characterized preclinical model of lung cancer brain metastasis.BMC cancer · 2020Article
- Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.Journal of medicinal chemistry · 2019Article
- Dosimetric evaluation of radionuclides for VCAM-1-targeted radionuclide therapy of early brain metastases.Theranostics · 2018Article
- Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.Breast cancer research and treatment · 2017Article
- Targeted Treatment of Brain Metastases.Current neurology and neuroscience reports · 2017Review
- Brain metastases as site of first and isolated recurrence of breast cancer: the role of systemic therapy after local treatment.Clinical & experimental metastasis · 2016Article
- Targeted Therapies for Brain Metastases from Breast Cancer.International journal of molecular sciences · 2016Review
- Perillyl Alcohol and Its Drug-Conjugated Derivatives as Potential Novel Methods of Treating Brain Metastases.International journal of molecular sciences · 2016Review
- Updates in the management of brain metastases.Neuro-oncology · 2016Review
- Article
- Strategies to target drugs to gliomas and CNS metastases of solid tumors.Journal of neurology · 2016Review
- EGFR and HER2 signaling in breast cancer brain metastasis.Frontiers in bioscience (Elite edition) · 2016Article
- Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling.Oncotarget · 2015Article
- Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?Current oncology reports · 2015Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer brain metastases (BCBMs) are common in patients with advanced disease. Breast cancer subtype and performance status are the major determinants of the course of the disease and survival time following a diagnosis of brain metastasis. Unique challenges specific to the management of BCBMs include overcoming the blood-brain barrier and resistance to conventional systemic therapies, as BCBMs typically occur in the pretreated patient population. The development of new systemic therapies for breast cancer, coupled with improvements in trial design, imaging modalities, and methods of defining and measuring clinical endpoints, has led to a renewed interest in developing novel therapeutic approaches for BCBMs. In this overview, we will review recent developments in the management of BCBMs and current prospective trials of systemic therapies specifically for patients with BCBMs, with a focus on novel pathway-specific therapies.
Indexed as
Identifiers
25144276W2289170664What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.